Clinical Trial Update: Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ranibizumab (Lucentis) investigating treatment of polypoidal choroidal vasculopathy across Phase 1 and Phase 2, with completed status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Southeast Retina Center, Georgia | Conditions: Polypoidal Choroidal Vasculopathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-06-23